Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease.

Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Abstract Text:

C Holmes,M McCulley,J A R Nicoll,J T Alder,C P L-H Chen,P T Francis,

A common intronic single nucleotide polymorphism (T102C) in the 5-HT2A receptor gene is associated with the development of different neuropsychiatric symptoms, including hallucinations and depressive symptoms in Alzheimer's disease (AD). Differential 5-HT2A receptor binding has also been associated with the development of these symptoms in AD. However, the relationship between 5-HT2A (T102C) genotype and 5-HT2A receptor binding in AD and control human brains has not been examined. We examined the association between different 5-HT2A (T102C) genotypes and [(3)H] ketanserin binding in the temporal and frontal cortex of 20 AD and 14 control human brains. In homozygotes, but not heterozygotes, there was a significant reduction in B(max) values for [(3)H] ketanserin binding in both areas of cortex in AD compared with control subjects. This study suggests a mechanism for the generation of different neuropsychiatric symptoms in AD from a single nucleotide polymorphism with reduced receptor binding in T102C 5-HT2A receptor gene homozygotes correlating with susceptibility to depressive symptoms, whereas the relative preservation of receptor binding in heterozygotes with AD correlating with susceptibility to hallucinations.

Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Publishing Authors By Initials

C Holmes,M McCulley,JA Nicoll,JT Alder,CP Chen,PT Francis,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Neuroscience letters

VOLUME: 420

Page Numbers: 58-60

Journal Abbreviation: Neurosci. Lett.

ISSN: 0304-3940

DAY: 8

MONTH: 04

YEAR: 2007

Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7600130

Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease.

AFFILIATION: University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Rd., Southampton, United Kingdom.

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Neurosci Lett

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Genetic variation in the 5-HT2A receptor and altered neocortical 3H ketanserin binding in Alzheimer's disease Related Publications

• 3D excretory MR urography: improved image quality with intravenous saline and diuretic administration.
• A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice.
• An affinity-based method for the purification of fluorescently-labeled biomolecules.
• Anomalous inferior vena cava drainage to portal vein offers a challenge to transcatheter ductus arteriosus closure.
• Congruency in homonymous hemianopia.
• Crossed pulmonary arteries.
• Cryo-SEM studies of latex/ceramic nanoparticle coating microstructure development.
• Determination of the abduction-adduction axis of rotation at the human knee: helical axis representation.
• Differences in Virulence among Escherichia coli O157:H7 Strains Isolated from Humans during Disease Outbreaks and from Healthy Cattle.
• Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system.
• Effects of language experience and stimulus complexity on the categorical perception of pitch direction.
• Evolving concepts in left ventricular systolic and diastolic remodeling: implications for therapy.
• Exploring new drugs for heart failure: the case of urocortin.
• Genetic variation in the 5-HT2A receptor and altered neocortical [(3)H] ketanserin binding in Alzheimer's disease.
• Interactions of uranium with polyphosphate.
• Low worldwide genetic diversity in the basking shark (Cetorhinus maximus).
• Magnetic resonance contrast agents from viral capsid shells: a comparison of exterior and interior cargo strategies.
• Modification of aniline containing proteins using an oxidative coupling strategy.
• Operator induced variability in left ventricular measurements with cardiovascular magnetic resonance is improved after training.
• Optics & refraction.
• Province-wide healthcare system integration challenge being solved in Alberta.
• Regioselective labeling of antibodies through N-terminal transamination.
• Response time in 14-year-olds with language impairment.
• Self-assembled cellular microarrays patterned using DNA barcodes.
• Self-assembling light-harvesting systems from synthetically modified tobacco mosaic virus coat proteins.
• TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats.
• TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol.
• The "ultimate sales machine"--7 ways to increase your lab's sales productivity.
• The implications of US experiences with early childhood interventions for the UK Sure Start Programme.
• The role of tissue factor pathway inhibitor in tumor growth and metastasis.